EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden

Woo-Hyoung Kang, Shin Hwang, Deok-Bog Moon, Ki-Hun Kim, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Byeong-Gon Na, Sang-Hoon Kim und 2 weitere

Transplant International · 2026

DOI: 10.3389/ti.2026.17121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2026. Verfasst von Woo-Hyoung Kang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seo…. Hauptthemen laut MEDLINE: Liver Transplantation, Carcinoma, Hepatocellular, Liver Neoplasms, ABO Blood-Group System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABO-incompatible (ABOi) living donor liver transplantation (LDLT) requires rituximab-based desensitization and intensified early immunosuppression, and whether this promotes hepatocellular carcinoma (HCC) recurrence remains controversial. We hypothesized that this effect depends on tumor burden, assessed morphologically (Milan criteria) and biologically (ADV score). In this single-center study, we analyzed 1,573 adults transplanted for HCC (ABOi, n = 316; ABO-compatible [ABOc], n = 1,257); the primary endpoint was recurrence-free survival (RFS). Crude recurrence was similar (21.8% vs. 20.7%; P = 0.64) despite a lower tumor burden in ABOi recipients. In a propensity score-matched cohort, RFS did not differ overall (hazard ratio 1.11, 95% CI 0.82–1.48), but beyond Milan recurrence was higher in ABOi recipients (53.7% vs. 38.5%; adjusted HR 1.45, 95% CI 1.00–2.09), whereas within Milan it was identical (13.3% vs. 13.4%). The same pattern held for tumor biology: recurrence was higher in ABOi only at ADV ≥5log (64.0% vs. 44.6%; P = 0.022). Higher early tacrolimus exposure in ABOi recipients was associated with recurrence. Overall survival was similar (P = 0.91). ABO-incompatibility did not compromise survival. Recurrence was higher in ABOi recipients with a high tumor burden by either measure, although the formal interaction tests were not significant (P = 0.23 and P = 0.088). These exploratory subgroup findings are hypothesis-generating and support closer early surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationCarcinoma, HepatocellularLiver NeoplasmsABO Blood-Group SystemBlood Group IncompatibilityNeoplasm Recurrence, LocalHumansLiving DonorsFemaleMaleMiddle AgedAdultTumor BurdenRetrospective StudiesDisease-Free SurvivalImmunosuppressive AgentsPropensity ScoreAged

Stichwörter der Autor:innen

ABO incompatibilityhepatocellular carcinoma (HCC)living donor liver transplantation (LDLT)recurrencesurveillance

Substanzen

ABO Blood-Group SystemImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Kang, W. H., Hwang, S., Moon, D. B., Kim, K. H., Ahn, C. S., Ha, T. Y., Song, G. W., Jung, D. H., Park, G. C., Yoon, Y. I., Na, B. G., Kim, S. H., Kim, S. M., & Lee, S. G. (2026). ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden. Transplant International. https://doi.org/10.3389/ti.2026.17121

Vancouver

Kang WH, Hwang S, Moon DB, Kim KH, Ahn CS, Ha TY, et al. ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden. Transplant International. 2026. doi:10.3389/ti.2026.17121

BibTeX
@article{Kang2026,
  author = {Kang, Woo-Hyoung and Hwang, Shin and Moon, Deok-Bog and Kim, Ki-Hun and Ahn, Chul-Soo and Ha, Tae-Yong and Song, Gi-Won and Jung, Dong-Hwan and Park, Gil-Chun and Yoon, Young-In and Na, Byeong-Gon and Kim, Sang-Hoon and Kim, Sung-Min and Lee, Sung-Gyu},
  title = {ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden},
  journal = {Transplant International},
  year = {2026},
  doi = {10.3389/ti.2026.17121}
}
Kostenlos starten →